CONNECTIVITY 2021: NEW HORIZONS
At our second CONNECTIVITY 2021 event, William Blair analysts and industry experts discussed how changes in healthcare technology are affecting the investing landscape.
Dr. Jennifer Doudna
Biochemist and Nobel-Prize-Winning Co-inventor of CRISPR Technology
CRISPR: Rewriting DNA and the Future of Humanity
CRISPR-Cas9 technology allows scientists to change the DNA of plants, animals, and humans with unprecedented precision, and is already revolutionizing the treatment of diseases previously believed to be incurable. Research into this technology also led to the advances used in COVID testing. At this event, Dr. Jennifer Doudna, who developed CRISPR-Cas9 alongside Emmanuelle Charpentier, discusses this amazing family of proteins; how technologies based on them can be responsibly used to revolutionize research, biomedicine, and agriculture; and how her Innovative Genomics Institute is playing a role.
Biology of the Living
CRISPR has evolved from a research tool to a cure for genetic disease (most notably, sickle cell disease). Doudna and her team are also exploring its use in making crops more drought resistant and enhancing the rate of methane metabolism in the soil, thereby remediating the eﬀects of climate change. Both these healthcare and agriculture advances create investment opportunities.
Scientists have a responsibility to be educators, says Doudna, whose Innovative Genomics Institute has established a public outreach team to work on making CRISPR an understandable science. “Our hope is to ﬁeld test our ‘products’ as they roll out of the lab, working directly with end users, like farmers, as they learn about these opportunities,” said Doudna.
Academia tends to build silos, putting scientists into specialty buckets. The Innovative Genomics Institute is seeking to change that. Plant biologists, for example, work side by side with clinical researchers who are developing CRISPR-based diagnostics. “They share discoveries,” says Doudna. “And when you have the right team and a focused eﬀort to do something, you can make rapid progress.”
James C. Foster
Chairman, President, and CEO, Charles River Laboratories
Thomas A. Sternberg
CFA, Partner, Global Equity Research Analyst, William Blair
Research Analyst, U.S. Growth and Core Equity Team, William Blair
Diagnosing the Future of Healthcare
Tomorrow’s Growth Themes
We have identiﬁed what we believe will
be key drivers of growth in the healthcare sector. These include new tools (such as gene sequencing) and new treatment modalities (such as gene editing). Other areas of interest for us include prevention and early detection; disruptive devices; whole-person care; outsourced research and development (R&D); and the IT companies helping move systems and processes to digital formats.
Cycle of Innovation
Small Companies Drive Breakthroughs
and midsize biotech companies that are
eﬀectively discovery engines. When they get to the commercialization stage, they license their technology or sell the company, then go discover something new. “Pipelines are robust, with funding coming from capital markets and big pharma,” says Charles River Laboratories’ James Foster. “This business hasn’t been cyclical for a long time.”
FEATURED WILLIAM BLAIR BLOG POSTS
Gain insights on macro market events, the economy, and investing strategies.
Gain More Insights
Our active ownership culture creates long-term client relationships by aligning with your interests and helping you achieve successful investment outcomes. Contact us to learn how we can partner with you.